Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.84 HKD 4.07% Market Closed
Market Cap: 2.6B HKD

Antengene Corporation Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Antengene Corporation Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Net Income (Common)
-ÂĄ581.2m
CAGR 3-Years
42%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.3B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
6%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Net Income (Common)
ÂĄ311.4m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.6B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Net Income (Common)?
Net Income (Common)
-581.2m CNY

Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Net Income (Common) amounts to -581.2m CNY.

What is Antengene Corporation Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-32%

Over the last year, the Net Income (Common) growth was 3%. The average annual Net Income (Common) growth rates for Antengene Corporation Ltd have been 42% over the past three years , -32% over the past five years .

Back to Top